FDA, Sanofi and Regeneron
FiercePharma · 1d
Sanofi, Regeneron look to seize major opportunity with Dupixent's COPD approval
After more than a decade without any therapeutic advancements in chronic obstructive pulmonary disorder (COPD), people with the progressive disease suddenly have two new options, with more likely o | Regeneron and Sanofi have announced that the FDA has expanded the label of megablockbuster Dupixent to treat COPD.
The American Journal of Manage… · 1d
FDA Approves Dupilumab as First Biologic Treatment for COPD
The FDA approved dupilumab today as the first biologic treatment for patients with uncontrolled chronic obstructive pulmonary disease (COPD) and an eosinophilic phenotype to significantly help reduce exacerbations and improve lung function.
Managed Healthcare Executive · 23h
FDA Approves Dupixent for Patients with COPD
After a delay, the FDA has approved Dupixent (dupilumab) as an add-on maintenance treatment of adults with inadequately controlled chronic obstructive pulmonary disease (COPD). Dupixent is the first biologic approved in the United States to treat these patients.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results